Resistance to autolysis in vancomycin-selected Staphylococcus aureus isolates precedes vancomycin-intermediate resistance.

Antimicrobial Agents and Chemotherapy
S Boyle-VavraR S Daum

Abstract

Four clinical U.S. glycopeptide intermediate resistant Staphylococcus aureus (GISA) isolates were resistant to Triton X-100-induced autolysis. Similar resistance was demonstrated in an isolate obtained after a single passage of a susceptible clinical isolate in low-level vancomycin. Strains with the vancomycin-induced Triton X-100 resistance phenotype produced active murein hydrolases but were resistant to lysis by murein hydrolases.

References

Oct 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·A Tomasz, S Waks
May 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·J V Höltje, A Tomasz
Oct 1, 1996·Journal of Bacteriology·E W Brunskill, K W Bayles
Apr 16, 1998·Microbiology·Steve A BlackmanSimon J Foster
Jun 22, 2001·Lancet·D A Ala'Aldeen, H Grundmann
Oct 27, 2001·The Journal of Antimicrobial Chemotherapy·S Boyle-VavraR S Daum

❮ Previous
Next ❯

Citations

Feb 1, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B P HowdenM L Grayson
Jul 9, 2011·Journal of the American Chemical Society·Jürgen EirichStephan A Sieber
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·N McCallumR Landmann
Jun 2, 2011·Antimicrobial Agents and Chemotherapy·Mitsutaka ShojiKeiichi Hiramatsu
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Sugunya UtaidaB J Wilkinson
Oct 23, 2012·International Journal of Antimicrobial Agents·Ting XueBaolin Sun
Apr 10, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Benjamin P HowdenTimothy P Stinear
Oct 29, 2013·International Journal of Medical Microbiology : IJMM·Bernd HesslingDörte Becher
Aug 30, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S LemaireP C Appelbaum
May 15, 2020·Clinical Microbiology Reviews·David M P De OliveiraMark J Walker
Jul 22, 2018·Journal of Materials Science. Materials in Medicine·John-Jairo Aguilera-CorreaJaime Esteban
Dec 25, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Yu-Mi LeeYang Soo Kim
Jan 15, 2021·International Journal of Medical Microbiology : IJMM·Jiade ZhuBaolin Sun
Mar 12, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Chulmin ParkYeun-Jun Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.